Validation of the CDC-RTI Diabetes Cost-Effectiveness Model
Abstract
The purpose of this study was to assess the validity of the CDC-RTI Diabetes Cost-Effectiveness Model by comparing rates of diabetes incidence and complications to existing published results. We performed 47 internal and external validation exercises comparing the model simulated outcomes with the outcomes from 24 published trials. To simulate the outcomes for each published study, we input a cohort with similar baseline characteristics and treatment and then modeled the development of diabetes and its complications for the same follow-up duration as in the trial. Outcomes measured included diabetes incidence, renal disease, neuropathy, retinopathy, cardiovascular disease, and mortality. The results of our model simulations were generally close to published outcomes. To determine how well our model was able to simulate the published outcomes, we ran three sets of simple regressions (actual outcome = b0 + b1 × simulated outcome)— one for the internal validation studies, one for the external validation studies, and one for the external validation studies of diabetes incidence. For the 17 internal validation analyses, the R2 value was 0.992 and the slope of the regression line was 1.001. For the 24 external validation analyses that did not include diabetes incidence, the R2 value was 0.969 and the slope of the regression line was 0.991; the six external validation analyses of diabetes incidence had an R2 value of 0.913. In conclusion, the CDC-RTI Diabetes Cost-Effectiveness…
How strong is the evidence?
Evidence Hub reads this as a cohort study. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.